

Evofosfamide

Catalog No: tcsc0616



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

918633-87-1

Formula:

$\text{C}_9\text{H}_{16}\text{Br}_2\text{N}_5\text{O}_4\text{P}$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility:

DMSO : 94 mg/mL (209.34 mM; Need ultrasonic and warming)

Alternative Names:

TH-302

Observed Molecular Weight:

449.04


Product Description

Evofosfamide (TH-302) is a **hypoxia**-activated prodrug with **IC₅₀** of 10 μ M and 1000 μ M in hypoxia (N₂) and normoxia (21% O₂), respectively.

IC50 & Target: Hypoxia-activated prodrug^[1]

In Vitro: Evofosfamide (TH-302) induces γ H2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G₂/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302)-mediated G₂/M arrest under both normoxia and hypoxia^[1].

In Vivo: Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized K^{trans} decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P[2]. A significant reduction in the hypoxic fraction (HF) to 2.1% \pm 4.7% is seen after 95% oxygen breathing (P2)^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!